• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on pharmacotherapy >Individualization of mycophenolate mofetil dose in renal transplant recipients.
【24h】

Individualization of mycophenolate mofetil dose in renal transplant recipients.

机译：肾移植受者中霉酚酸酯的个体化剂量。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The immunosuppressive agent mycophenolate mofetil has been successfully used over the past 10 years to prevent acute allograft rejection after renal transplantation. It has mainly been administered as a fixed dose of mycophenolate mofetil 1000 mg b.i.d. The pharmacokinetics of mycophenolic acid, the active moiety of the prodrug mycophenolate mofetil, show large between-patient variability, and exposure to mycophenolic acid correlates with the risk for acute rejection. This suggests that already excellent clinical results can be further improved by mycophenolate mofetil dose individualization. This review discusses different arguments in favour of individualization of mycophenolate mofetil dose, as well as strategies for managing mycophenolate mofetil therapy individualization, including pharmacokinetic and pharmacodynamic monitoring and dose individualization based on pharmacogenetic information. It is expected that pharmacokinetic monitoring of mycophenolic acid will offer the most effective and feasible tool for mycophenolate mofetil dose individualization.
机译：在过去的十年中，免疫抑制剂霉酚酸酯已成功用于预防肾移植后的急性同种异体移植排斥反应。它主要以固定剂量的霉酚酸酯（mocophenolate mofetil）1000 mg b.i.d.给药。霉酚酸（前药霉酚酸酯的活性部分）的药代动力学表现出较大的患者差异，暴露于霉酚酸与急性排斥反应的风险相关。这表明已经可以通过霉酚酸酯的剂量个体化进一步改善已经非常好的临床结果。这篇综述讨论了赞成麦考酚酸酯活性剂量个体化的不同论点，以及管理麦考酚酸酯活性治疗个体化的策略，包括药代动力学和药效学监测以及基于药代遗传学信息的剂量个体化。预计霉酚酸的药代动力学监测将为霉酚酸酯的剂量个体化提供最有效和可行的工具。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号